Literature DB >> 12446956

Genetic alterations in presumptive precursor lesions of breast carcinomas.

Michaela Aubele1, Martin Werner, Heinz Höfler.   

Abstract

The hypothetical multistep model of breast carcinogenesis suggests a transition from normal epithelium to invasive carcinoma via intraductal hyperplasia (without and with atypia) and in situ carcinoma. These presumptive precursor lesions are currently defined by their histological features, and their prognosis is imprecisely estimated from indirect epidemiological evidence. Cytogenetic and molecular-genetic analysis of these lesions give evidence for an accumulation of various genetic alterations during breast tumorigenesis. Using immuno-histochemistry overexpression of the c-erbB-2 oncogene was found in ductal carcinoma in situ (DCIS), but not in atypical intraductal hyperplasia (AIDH) and intraductal hyperplasia (IDH). An expression of mutant p53 tumor suppressor gene as well as expression of cyclin D1 was identified in DCIS. In IDH lesions loss of heterozygosity (LOH) at various loci could be identified, and comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) studies delivered evidence for DNA amplification on chromosomal region 20q13 in the early stage of IDH.However, little is currently known about genetic alterations in those premalignant lesions, and the chronology of genetic alterations and histopathological changes during carcinogenesis is mainly undiscovered.

Entities:  

Mesh:

Year:  2002        PMID: 12446956      PMCID: PMC4618575          DOI: 10.1155/2002/371680

Source DB:  PubMed          Journal:  Anal Cell Pathol        ISSN: 0921-8912            Impact factor:   2.916


  7 in total

1.  Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.

Authors:  Noa Rivlin; Ran Brosh; Moshe Oren; Varda Rotter
Journal:  Genes Cancer       Date:  2011-04

Review 2.  Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis.

Authors:  Cheng-Jeng Tai; Chung-Huei Hsu; Shing-Chuan Shen; Woan-Ruoh Lee; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2010-08-11

3.  Adiposity is associated with p53 gene mutations in breast cancer.

Authors:  Heather M Ochs-Balcom; Catalin Marian; Jing Nie; Theodore M Brasky; David S Goerlitz; Maurizio Trevisan; Stephen B Edge; Janet Winston; Deborah L Berry; Bhaskar V Kallakury; Jo L Freudenheim; Peter G Shields
Journal:  Breast Cancer Res Treat       Date:  2015-09-12       Impact factor: 4.872

4.  The PR status of the originating cell of ER/PR-negative mouse mammary tumors.

Authors:  J Dong; W Zhao; A Shi; M Toneff; J Lydon; D So; Y Li
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

Review 5.  Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.

Authors:  Flora Zagouri; Theodoros N Sergentanis; George C Zografos
Journal:  World J Surg Oncol       Date:  2007-05-31       Impact factor: 2.754

6.  CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.

Authors:  José Roberto F Caldeira; Erika C Prando; Francisco C Quevedo; Francisco A Moraes Neto; Cláudia A Rainho; Silvia R Rogatto
Journal:  BMC Cancer       Date:  2006-03-02       Impact factor: 4.430

Review 7.  Genetic alteration and gene expression modulation during cancer progression.

Authors:  Cathie Garnis; Timon P H Buys; Wan L Lam
Journal:  Mol Cancer       Date:  2004-03-22       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.